The safety of treatment options for elderly people with acute myeloid leukemia

Abstract : INTRODUCTION: Life expectancy in elderly patients with acute myeloid leukemia (AML) is a function of age, disability, and co-morbidity, combined with leukemia characteristics. There is currently no consensus regarding the optimal therapeutic strategy for older adults with AML. Although selected older adults with AML can benefit from intensive therapies, recent evidence supports the use of lower-intensity therapies in most patients and emphasizes the importance of tolerability and quality of life. AREAS COVERED: Results of the current clinical trials and safety data are reviewed. EXPERT OPINION: Treatment recommendations for elderly patients with AML need to be individualized. In order to avoid toxicities, hematologists should collaborate more with geriatricians to identify clues of vulnerability in elderly patients through the study of functional physical, physiological, cognitive, social, and psychological parameters
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-lyon1.archives-ouvertes.fr/hal-01796187
Contributor : Lauriane Pillet <>
Submitted on : Saturday, May 19, 2018 - 11:34:08 AM
Last modification on : Friday, May 25, 2018 - 4:50:07 PM

Identifiers

Collections

Citation

Xavier Thomas, Caroline Le Jeune. The safety of treatment options for elderly people with acute myeloid leukemia. Expert Opinion on Drug Safety, Informa Healthcare, 2016, 15, pp.1-11. ⟨http://www.tandfonline.com/doi/full/10.1517/14740338.2016.1161020⟩. ⟨10.1517/14740338.2016.1161020⟩. ⟨hal-01796187⟩

Share

Metrics

Record views

45